EUVIMEDDescubrir EUVIMED
Open access · CC BY-NC-ND 4.0

Blockade of Annexin A2 Prevents Early Microvasculopathy in Murine Models of Diabetic Retinopathy

Valentina Dallacasagrande, Wei Liu, Dena Almeida, Min Luo, Katherine A Hajjar

Investigative Opthalmology & Visual Science · 2023-04-27 · 64 (4) · 33

DOI: 10.1167/iovs.64.4.33 ↗

At a glance

Journal article in Investigative Opthalmology & Visual Science, published on 2023-04-27. Written by Valentina Dallacasagrande and 4 co-authors. Institution: Department of Pediatrics, Weill Cornell Medicine, New York, New York, United States. Major MEDLINE topics: Annexin A2, Diabetes Mellitus, Diabetic Retinopathy, Retinal Diseases. Cited 8 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Purpose

We examined the role of annexin A2 (A2) in the development of diabetic retinal vasculopathy by testing the effect of Anxa2 gene deletion as well as administration of anti-A2 antibodies on pericyte dropout and retinal neovascularization in diabetic Akita mice, and in mice subjected to oxygen-induced retinopathy.

Methods

We analyzed diabetic Ins2AKITA mice with or without global deletion of Anxa2, as well as Ins2AKITA mice that received intravitreal anti-A2 IgG or control antibody at 2, 4, and 6 months, for retinal pericyte dropout at 7 months of age. In addition, we assessed the effect of intravitreal anti-A2 on oxygen-induced retinopathy (OIR) in neonatal mice by quantifying retinal neovascular and vaso-obliterative area, and by enumeration of neovascular tufts.

Results

Both deletion of the Anxa2 gene and immunologic blockade of A2 prevented pericyte depletion in retinas of diabetic Ins2AKITA mice. Blockade of A2 also reduced vaso-obliteration and neovascularization in the OIR model of vascular proliferation. This effect was amplified when a combination of antivascular endothelial growth factor (VEGF) and anti-A2 antibodies was used.

Conclusions

Therapeutic approaches that target A2, alone or in combination with anti-VEGF therapy, are effective in mice, and may also curtail the progression of retinal vascular disease in humans with diabetes.

Subjects

MeSH terms (MEDLINE)

Annexin A2Diabetes MellitusDiabetic RetinopathyRetinal DiseasesRetinal NeovascularizationAnimalsMiceDisease Models, AnimalMice, Inbred C57BLOxygenVascular Endothelial Growth Factor A

Substances

Annexin A2OxygenVascular Endothelial Growth Factor AAnxa2 protein, mouse

Authors and institutions

  • Department of Pediatrics, Weill Cornell Medicine, New York, New York, United States.
  • Department of Medicine, Weill Cornell Medicine, New York, New York, United States.

Cite

APA

Dallacasagrande, V., Liu, W., Almeida, D., Luo, M., & Hajjar, K. A. (2023). Blockade of Annexin A2 Prevents Early Microvasculopathy in Murine Models of Diabetic Retinopathy. Investigative Opthalmology & Visual Science, 64(4), 33. https://doi.org/10.1167/iovs.64.4.33

Vancouver

Dallacasagrande V, Liu W, Almeida D, Luo M, Hajjar KA. Blockade of Annexin A2 Prevents Early Microvasculopathy in Murine Models of Diabetic Retinopathy. Investigative Opthalmology & Visual Science. 2023;64(4):33. doi:10.1167/iovs.64.4.33

BibTeX
@article{Dallacasagrande2023,
  author = {Dallacasagrande, Valentina and Liu, Wei and Almeida, Dena and Luo, Min and Hajjar, Katherine A},
  title = {Blockade of Annexin A2 Prevents Early Microvasculopathy in Murine Models of Diabetic Retinopathy},
  journal = {Investigative Opthalmology & Visual Science},
  year = {2023},
  volume = {64},
  number = {4},
  pages = {33},
  doi = {10.1167/iovs.64.4.33}
}
Start for free →